Paxman AB (publ) (PAX.ST)
SEK 62.2
(-3.72%)
SEK 62.2
(-3.72%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 44.5 Million SEK | -25.52% |
| 2022 | 59.76 Million SEK | 47.25% |
| 2021 | 40.58 Million SEK | -38.62% |
| 2020 | 66.12 Million SEK | 16.8% |
| 2019 | 56.61 Million SEK | 86.56% |
| 2018 | 30.34 Million SEK | 136.33% |
| 2017 | 12.84 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 47.8 Million SEK | 7.39% |
| 2024 Q2 | 44.48 Million SEK | -6.94% |
| 2023 Q4 | 44.5 Million SEK | -22.6% |
| 2023 Q3 | 57.5 Million SEK | -1.24% |
| 2023 FY | 44.5 Million SEK | -25.52% |
| 2023 Q1 | 57.24 Million SEK | -4.21% |
| 2023 Q2 | 58.22 Million SEK | 1.72% |
| 2022 Q3 | 52.69 Million SEK | 12.99% |
| 2022 FY | 59.76 Million SEK | 47.25% |
| 2022 Q1 | 42.05 Million SEK | 3.61% |
| 2022 Q4 | 59.76 Million SEK | 13.42% |
| 2022 Q2 | 46.63 Million SEK | 10.89% |
| 2021 Q3 | 59.01 Million SEK | -1.05% |
| 2021 Q4 | 40.58 Million SEK | -31.23% |
| 2021 FY | 40.58 Million SEK | -38.62% |
| 2021 Q1 | 55.03 Million SEK | -16.77% |
| 2021 Q2 | 59.64 Million SEK | 8.39% |
| 2020 FY | 66.12 Million SEK | 16.8% |
| 2020 Q3 | 66.8 Million SEK | 8.26% |
| 2020 Q4 | 66.12 Million SEK | -1.03% |
| 2020 Q2 | 61.71 Million SEK | -2.89% |
| 2020 Q1 | 63.54 Million SEK | 12.25% |
| 2019 Q4 | 56.61 Million SEK | 17.83% |
| 2019 Q3 | 48.04 Million SEK | 6.02% |
| 2019 Q1 | 37.51 Million SEK | 23.63% |
| 2019 FY | 56.61 Million SEK | 86.56% |
| 2019 Q2 | 45.31 Million SEK | 20.79% |
| 2018 Q3 | 21.22 Million SEK | 39.33% |
| 2018 FY | 30.34 Million SEK | 136.33% |
| 2018 Q1 | 12.63 Million SEK | -1.6% |
| 2018 Q4 | 30.34 Million SEK | 42.94% |
| 2018 Q2 | 15.23 Million SEK | 20.6% |
| 2017 FY | 12.84 Million SEK | 0.0% |
| 2017 Q2 | 10.3 Million SEK | 2308.64% |
| 2017 Q1 | 428 Thousand SEK | 0.0% |
| 2017 Q4 | 12.84 Million SEK | 8.35% |
| 2017 Q3 | 11.85 Million SEK | 14.96% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -304.701% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.336% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.336% |
| Arcoma AB | 33.3 Million SEK | -33.641% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 86.5% |
| BICO Group AB (publ) | 3.26 Billion SEK | 98.637% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 84.098% |
| CellaVision AB (publ) | 212.32 Million SEK | 79.037% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -213.51% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -547.975% |
| C-Rad AB (publ) | 122.4 Million SEK | 63.636% |
| Duearity AB (publ) | 17.53 Million SEK | -153.902% |
| Dignitana AB (publ) | 37.56 Million SEK | -18.479% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -124.793% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.82% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -116.06% |
| Iconovo AB (publ) | 14.55 Million SEK | -205.822% |
| Integrum AB (publ) | 22.07 Million SEK | -101.646% |
| Luxbright AB (publ) | 7 Million SEK | -535.832% |
| Mentice AB (publ) | 163.55 Million SEK | 72.786% |
| OssDsign AB (publ) | 105.25 Million SEK | 57.714% |
| Promimic AB (publ) | 16.15 Million SEK | -175.495% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 28.406% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -109.178% |
| ScandiDos AB (publ) | 37.18 Million SEK | -19.693% |
| Sectra AB (publ) | 1.64 Billion SEK | 97.288% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -1.014% |
| Senzime AB (publ) | 58.06 Million SEK | 23.346% |
| SpectraCure AB (publ) | 14.97 Million SEK | -197.222% |
| Stille AB | 172.64 Million SEK | 74.219% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 98.787% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 82.237% |